MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

JNJ-38877618

MCE 国际站：JNJ-38877618

品牌：MedChemExpress (MCE)

货号：HY-111050

CAS 号：943540⁻⁷4⁻⁷

生物活性： JNJ-38877618 是一种强效、高选择性、口服生物利用度高的 Met 激酶抑制剂，对野生型 Met 和突变型 Met 的 IC50 分别为 2 nM 和 3 nM。

体外研究(In Vitro)：OMO-1 (formerly JNJ-38877618), is a potent, highly selective, orally bioavailable Met kinase inhibitor with nM binding affinity (Kd=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant Met (2 and 3 nM IC50). Met inhibitory effects are assessed in proliferation, colony formation and motility assays. JNJ-38877618 displays nM potency against Met Ampl/mutant and therapy resistant models[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。

体内研究(In Vivo)：JNJ-38877618 induces complete inhibition of tumor growth in 3 models: the SNU5 Met amp gastric, U87-MG HGF autocrine glioblastoma and Hs746T Met exon 14 skipping mutant gastric cancer. JNJ-38877618 induces regression of large Met amplified EBC-1 SqNSCLC where JNJ-38877618 leads to dose- and time-dependent inhibition of Met kinase activation, with the duration of target shut down considerably exceeding plasma exposure times. Combination treatments are well tolerated and improved EGFR targeted therapy[1]. MCE尚未独立确认这些方法的准确性。 仅供参考。

分子量：374.35

Formula：C20H12F2N6

性状：固体

颜色：White to off-white

运输条件：美国大陆地区的室温；其他地区可能有所不同。

储存方式：粉末 -20°C 3年

提供质量检测报告：Data Sheet、SDS、COA、HNMR、LCMS、产品使用指南

产品活性：JNJ-38877618是一种有效的，高选择性的，口服可用的 (Met) 激酶抑制剂，对于野生型和突变体的 IC50 值分别为2和3 nM。

IC50 & Target：IC50: 2 nM (wt Met), 2 nM (mutant Met)[1]

相关产品：SRI 31215 TFA | Tyrosine kinase inhibitor | Glumetinib | Ensartinib dihydrochloride | BMS⁻⁷94833 | PHA-665752 | Afatinib | Foretinib | Afatinib (Standard) | Elzovantinib | Ningetinib | Ensartinib

热门产品线：抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类

Trending products：Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides

参考文献：
[1]. Libouban M, et al. OMO-1, a potent, highly selective, orally bioavailable, Met kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against Met pathway-driven tumors, and EGFR TKI combination activity in acquire